dpp-4 inhibitor and glp-1 receptor agonist combination versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Were DPP-4 inhibitors the original

2018 Adverse Events: 1,059 2019 Adverse Events: 1,246 2020 Adverse Events: 2,781 2021 Adverse Events: 4,001 2022 Adverse Events: 5,851 2023 Adverse Events: (As of June 30, 2023) 3,908 According to the FDAs database, the number of adverse events reported for each semaglutide drug since they have been released up until June 30, 2023, are as follows

As the landscape rapidly evolves, the question of the best GLP-1 for weight loss, especially the comparison between oral and injectable semaglutide has never been more relevant

These metabolic differences are generally modest compared to the dramatic difference in total weight loss

Both the FDA and the European Medicines Agency are also now considering the approval of semaglutide for the treatment of chronic kidney diseases in patients with type 2 diabetes (Manalac, June 2024